Sintx Technologies, Inc. Q2 FY2026 earnings call

Overall Transition Progress

• SINTX achieved meaningful progress in its transition from a development-stage firm to a commercially focused biomaterials and medical technology platform company, with commercial activity now visible in financial results.
• The company’s two complementary business model is fully established: contract manufacturing/OEM provides near-term revenue, customer validation, manufacturing utilization and operating leverage, while the proprietary silicon nitride medical platform delivers long-term value via differentiated products, licensing, distribution and strategic partnership opportunities. Both segments rely on shared U.S.-based manufacturing, material science, and regulatory capabilities.

Financing and Liquidity Updates

• The company completed Q2 2026 financing transactions generating approximately $5 million in gross proceeds, primarily from a June private placement and sales under its at-the-market (ATM) equity program.
• As of June 30, 2026, SINTX held $3.6 million in cash and cash equivalents, with $4.8 million in stockholders’ equity. Substantial doubt regarding the company’s ability to continue as a going concern remains, as disclosed in the Q2 10-Q filing.

Contract Manufacturing Operations

• The segment received new aggregate purchase orders exceeding $3.2 million from existing customers, with production and shipments already underway and set to continue into 2027. Management emphasizes that order value does not equal recognized revenue, and key milestones include qualified production, on-time shipment, customer acceptance, cash collection and repeat orders.
• Management is aligning production schedules to customer requirements, managing working capital for raw materials and work-in-progress, and maintaining disciplined growth to avoid unsustainable working capital pressure or quality compromises.

Proprietary Medical Commercialization

• The lead product, SiNAPTIC Foot & Ankle Osteotomy Wedge System, received FDA 510(k) clearance in late 2025, achieved first U.S. clinical use in March 2026, and generated initial commercial revenue in Q2 2026, marking the company’s shift from R&D/regulatory development to clinical and commercial activity.
• Near-term focus is on building a capital-efficient commercial foundation rather than unprofitable growth. Management is evaluating multiple go-to-market models (direct-to-surgeon, distributors, strategic partnerships) to access surgeons without building an overly large sales infrastructure disproportionate to current revenue.
• The broader silicon nitride platform has potential applications across orthopedics, spine, dental and wound care, but management is prioritizing programs based on time to revenue, capital requirements, regulatory pathways and partner interest.
• A board member and his firm, Southern Metrics, have been engaged to evaluate inbound strategic partnership, licensing and business development opportunities; no specific transaction is currently pending.

Cost Structure and Expense Management

• Expense classification was updated to reflect the shift to commercialization: sales and marketing expenses increased to support product launch, while reported R&D expense declined due to overhead reallocation to general and administrative (G&A) expenses, not a reduction in underlying technical activity.
• Management is currently evaluating all spending (staffing, external services, facilities, project priorities) through the lens of commercial return, with the goal of aligning cost structure to current business scale and deploying capital to high-value opportunities, rather than blanket spending cuts.

SINTX Technologies operates across two core business segments: Contract Manufacturing/OEM, and Proprietary Medical Products. For Q2 2026, total company revenue was $452,000, a 199% year-over-year (YoY) increase. Product revenue across both segments totaled $447,000 (98.9% of total revenue), growing 347% YoY, while small grant and contract revenue made up the remaining $5,000 (1.1% of total revenue), down from $51,000 YoY. The Contract Manufacturing/OEM segment drove most Q2 2026 product revenue growth, with increased customer demand and improved pricing contributing to performance. This segment received aggregate new purchase orders exceeding $3.2 million in Q2 2026, with production and shipments scheduled to continue into 2027. The Proprietary Medical Products segment, led by the SiNAPTIC Osteotomy Foot & Ankle Wedge System, generated initial commercial revenue in Q2 2026 following first clinical use in March 2026. Gross profit company-wide was $278,000 (61.5% of total revenue), growing 388% YoY, with gross margin improving to 61.5% from 37.7% YoY, driven by favorable sales mix, higher-margin product sales, and improved pricing in the OEM segment.

• Management expects Q3 2026 total revenue to fall in the range of $900,000 to $1.1 million, and Q4 2026 total revenue to fall in the range of $1 million to $1.3 million.
• All guidance is subject to significant uncertainty related to production timing, customer scheduling, manufacturing execution, and revenue recognition timing, so actual results may differ materially from current projections. The $3.2 million in announced purchase orders provide commercial visibility, but revenue recognition depends on meeting production, shipment and customary customer requirements.
• As of June 30, 2026, the company has approximately $5.1 million in remaining capacity under its 2025 ATM equity program, which remains available as a source of future capital.

• Substantial doubt regarding SINTX Technologies’ ability to continue as a going concern remains disclosed in the company’s Q2 2026 Form 10-Q, driven by ongoing net operating losses and ongoing liquidity needs.
• Revenue recognition of the $3.2 million in new contract manufacturing purchase orders is subject to multiple risks, including production delays, quality issues, material availability, yield challenges, changing customer requirements, and failure to secure customer acceptance or collect cash.
• Commercial adoption of the SiNAPTIC Foot & Ankle Wedge System depends on surgeon adoption, channel development, product availability, reimbursement and market factors, with no guarantee of successful commercialization even after regulatory clearance and initial clinical use.
• Gross margin may fluctuate quarter-to-quarter based on changes in product mix, pricing, manufacturing efficiency and customer demand, so the elevated Q2 2026 gross margin is not expected to be sustained in all future periods.
• The company’s current cost structure remains high relative to its small current revenue base, and cost alignment efforts may not deliver sufficient savings to improve operating results.
• Growth of contract manufacturing could create excessive working capital pressure or quality compromises if not managed properly, leading to unsustainable results.

No question and answer section was included in the provided earning call transcript.